Compounded Semaglutide Dosage Chart & Guide
Understand prescribed amounts, concentration and U-100 scale conversions without confusing an arithmetic chart with a treatment plan. These adult-regimen examples need to be matched to the actual prescription, preparation and measuring device.
Understanding Compounded Semaglutide Dosing Fundamentals
A concentration describes the labeled amount in each milliliter of the preparation. For example, 1 mg/mL means one milligram per milliliter, so a prescribed 0.25 mg amount would correspond to 0.25 mL. Confirm that the label states a concentration rather than only the total milligrams in the container.
Compounded preparations can differ in active form, other ingredients, concentration and packaging. They are not FDA-approved generic versions of Ozempic or Wegovy. Equal stated milligrams do not establish identical clinical effects or finished-product quality.
These distinctions have practical consequences. A published poison-center case series describes three semaglutide administration-error cases involving products obtained from compounding pharmacies and an aesthetic spa. It illustrates a measurement and counseling problem, not an estimate of the failure rate of all compounded products.
Standard Semaglutide Titration Schedule
There is no single standard compounded schedule shared by all Ozempic and Wegovy products. For initial treatment with their weekly injections, 0.25 mg for four weeks is a starting step; later escalation and maintenance differ. The examples here are not pediatric, tablet or switching instructions.
The Wegovy injection label includes successive four-week stages of 0.25, 0.5, 1 and 1.7 mg before the usual 2.4 mg maintenance dose. It allows delayed escalation for tolerability. Current labeling also includes a higher-dose option for selected adults, so 2.4 mg should not be described as the universal maximum. None of this assigns a regimen to a compounded vial.
The Ozempic label has separate maintenance and escalation instructions. Do not jump from 1 mg to 2.4 mg at week 13, accelerate to two-to-three-week steps from this guide, or transfer a tablet dose to an injection.
Compounded Semaglutide Dosage Chart
The original example amounts and concentrations are retained below as arithmetic, not recommended volumes or an automatic week-by-week schedule. Check the prescribed amount and actual vial concentration; the examples do not describe all available formulations.
| Example amount (mg) | Volume at 1 mg/mL | Volume at 2.5 mg/mL | Volume at 5 mg/mL |
|---|---|---|---|
| 0.25 | 0.25 mL | 0.1 mL | 0.05 mL |
| 0.5 | 0.5 mL | 0.2 mL | 0.1 mL |
| 1 | 1 mL | 0.4 mL | 0.2 mL |
| 1.7 | 1.7 mL | 0.68 mL | 0.34 mL |
| 2.4 | 2.4 mL | 0.96 mL | 0.48 mL |
At 1 mg/mL, the 1.7 and 2.4 mg examples require more than 1 mL. That exceeds a 1 mL syringe but does not authorize multiple injections, a different device or a concentration change. Ask the pharmacy to resolve a mismatch. Smaller syringes have lower capacities, and fitting in a barrel does not establish injection suitability.
Syringe Unit Conversions for Accurate Dosing
Volume (mL) = prescribed amount (mg) ÷ concentration (mg/mL). Only on a confirmed U-100 scale does volume × 100 give U-100 units. That scale unit is not a biological unit of semaglutide and is not interchangeable with a pen setting or another insulin scale.
1 mg/mL examples: 0.25 mg = 25 U-100 units; 0.5 mg = 50 U-100 units; 1 mg = 100 U-100 units; 1.7 mg = 170 U-100 units; 2.4 mg = 240 U-100 units. Confirm capacity and graduation spacing separately.
2.5 mg/mL examples: 0.25 mg = 10 U-100 units; 0.5 mg = 20 U-100 units; 1 mg = 40 U-100 units; 1.7 mg = 68 U-100 units; 2.4 mg = 96 U-100 units. Confirm capacity and graduation spacing separately.
5 mg/mL examples: 0.25 mg = 5 U-100 units; 0.5 mg = 10 U-100 units; 1 mg = 20 U-100 units; 1.7 mg = 34 U-100 units; 2.4 mg = 48 U-100 units. Confirm capacity and graduation spacing separately.
The manufacturer's device guide lists different barrel capacities and half-unit scales on selected syringes. Not every insulin syringe holds 1 mL or has the same markings. Graduation spacing is not a guarantee of accuracy.
Ask the pharmacy to show the correct fill level on the actual supplied device and give matching written instructions. Recheck when a refill changes concentration; the same number of scale units may then contain a different amount of medication.
How Compounded Semaglutide Concentrations Affect Dosing
For a fixed prescribed amount, increasing concentration decreases volume. This does not establish a universal best concentration or show that most pharmacies favor a particular one.
For the 0.25 mg example: at 1 mg/mL, the volume is 0.25 mL; at 2.5 mg/mL it is 0.1 mL; at 5 mg/mL it is 0.05 mL. Relative to 0.25 mL, those latter volumes are 40% and 20%, respectively—not one tenth and one twentieth. A tenth or twentieth of one milliliter is a different comparison.
On a U-100 scale, a one-unit difference is 0.01 mL. At 5 mg/mL that represents 0.05 mg, which is 20% of the 0.25 mg example. This is arithmetic illustrating the effect of a measurement difference, not an acceptable-error threshold or a prediction of a particular syringe's performance.
The pharmacy should match concentration, container, device and instructions to the prescription. Do not dilute, combine vials or choose a new concentration to make this page's examples fit.
Injection Technique for Compounded Semaglutide
Obtain training for the exact preparation and supplied device. Confirm the prescribed mg amount, concentration, volume and scale before measuring. A correctly calculated volume does not establish that a medication or regimen is appropriate.
Follow the preparation's inspection, warming, site and administration instructions; there is no universal waiting time or needle angle for every device. Added ingredients can change expected appearance. Unexpected changes need assessment, while a clear-looking solution does not establish sterility.
Use new sterile equipment as instructed, do not share patient-use medication or devices, and dispose of sharps appropriately. CDC injection-safety guidance explains handling principles; a generic article does not replace device-specific training.
Comparing Compounded to Brand Semaglutide Dosing
Approved brand products and compounded preparations should be compared at the finished-product level: active ingredient form, other ingredients, formulation, concentration, device, storage and supporting evidence. Matching the nominal mg amount alone is not proof of equal weight loss, glucose effects or adverse events.
The FDA dosing-error report describes varying compounded concentrations and packaging, and reports semaglutide salt forms different from the ingredient in approved products. Its historical device list should not be treated as a complete list of today's brand presentations; use current product instructions.
Brand devices are not all operated by dialing a dose, and compounded preparations are not necessarily supplied only in multidose vials. Do not draw medication out of a pen or convert a tablet based on this page.
Compare current all-in costs and eligibility for coverage or manufacturer programs. A compounded product is not automatically cheaper for every patient, and no fixed saving is established here. Compounding can serve a clinical need, but an individual preparation's suitability and supply requirements need confirmation.
Dose Adjustments and Maintenance Dosing
The prescriber selects maintenance according to the product, indication, response and tolerability. A maximum dose is not a target for everyone, and being at a particular week does not determine a dose.
Persistent or severe symptoms warrant clinical advice, not a promise that they will disappear after four weeks. Seek urgent assessment for severe abdominal pain, inability to keep fluids down or signs of a serious allergic reaction. Important contraindications and interactions are described in the product labels and require a medication review.
Discuss changes, interruptions and stopping with the prescriber. This page does not establish that abrupt discontinuation is appropriate for every person or that restarting at a previous dose is appropriate after a gap. A conversion table cannot account for changes in diabetes treatment or other medicines.
Safety and Quality Considerations
Check the dispensing pharmacy's license and contact details, the complete ingredient list, the actual concentration, storage instructions and any relevant lot-specific testing. Accreditation can inform diligence; it is not proof that a particular vial is equivalent to an approved product.
Do not interpret “FDA-registered supplier” or “pharmaceutical grade” as FDA approval of a compounded finished product. A raw-material certificate of analysis does not by itself establish finished-vial potency, sterility or stability through its beyond-use date.
If the label, prescription and syringe instructions disagree, obtain clarification before use. The FDA report and poison-center cases above show why a mismatch should be resolved with the pharmacy rather than by guessing from online charts.
Report suspected product problems to the pharmacy and unexpected symptoms to the treating clinician. This article does not verify a specific supplier's manufacturing process, legal availability or clinical suitability.
Storage, Stability, and Handling
Use the preparation's required temperature and unopened expiry or beyond-use date. For compounded GLP-1 multidose vials, FDA currently recommends discarding within 28 days after first use, even when the compounder gives a longer interval. This addresses contamination risk, not a guaranteed 28-day chemical stability period or a room-temperature allowance. A shorter supplied limit still applies; ask the pharmacy to reconcile conflicting instructions before further use.
Approved semaglutide injection instructions prohibit freezing, but that does not establish a universal chemical explanation for every preparation. If a compounded product freezes or has an uncertain storage excursion, set it aside and ask the dispensing pharmacy before further use. Returning it to the refrigerator does not reset a date.
Home-drawn syringes are not equivalent to manufacturer-filled or pharmacy-prepared syringes with validated instructions. Keep the original label and use a suitable travel system that does not freeze a no-freeze medicine. See the storage and travel guide for product-specific examples.
Editorial update, September 8, 2026: corrected relative-volume arithmetic, syringe-scale claims, product/titration distinctions, unsupported equivalence and storage guidance. Arithmetic examples were independently checked; this is not clinical clearance of a preparation. Sourcing and corrections policy.
Related Guides & Resources
Frequently Asked Questions
There is no single compounded schedule shared by Ozempic and Wegovy. Their injectable products start with 0.25 mg weekly for four weeks, but later escalation and maintenance differ. The Wegovy injection pathway includes a 1.7 mg stage before the usual 2.4 mg dose; it does not jump from 1 mg to 2.4 mg at week 13. Follow the exact prescription and current product-specific instructions, not an automatic calendar or a faster two-to-three-week escalation.
This page uses 1, 2.5 and 5 mg/mL for arithmetic examples, not as the only available concentrations or a statement of pharmacy preferences. At a prescribed amount of 0.25 mg, those concentrations would require 0.25, 0.1 and 0.05 mL respectively. Check the actual vial label every time; a refill may have different instructions.
First divide the prescribed mg amount by the vial concentration in mg/mL to get mL. Only when the supplied device is U-100 does multiplying that volume by 100 give U-100 scale units. For example, 0.25 mg at 2.5 mg/mL is 0.1 mL, or 10 U-100 units. Do not use this conversion for a different syringe scale, a pen or a tablet. A numerical result also does not establish device capacity or a suitable injection volume.
Compounded preparations are not FDA-approved generic versions of Ozempic or Wegovy, and equal stated milligrams do not prove clinical equivalence. The active form, other ingredients, concentration, container, testing and directions matter. FDA has reported semaglutide salt forms that differ from the ingredient in approved products. Prices and presentation types should be checked directly rather than assumed.
Concentration should be matched to the prescription and actual measuring device by the pharmacy. Higher concentration reduces the required volume but increases the amount represented by each scale division. Barrel capacity, graduation spacing and user training all matter; this page does not establish a universal best concentration or claim that every insulin syringe has half-unit markings.
Use the preparation’s required temperature and unopened expiry or beyond-use date. FDA currently recommends discarding compounded GLP-1 multidose vials within 28 days after first use even if the compounder gives a longer interval. A shorter supplied limit still applies. This contamination-risk recommendation is not proof of 28-day chemical stability or a room-temperature allowance. Ask the pharmacy about conflicting instructions, freezing or an uncertain excursion before further use. Prefilled devices and prepared syringes have their own instructions.